The newest clinical study (the “Study”) on Beachbody’s
superfood nutrition shake named Shakeology® (“Shakeology”)
has just been published in the Journal of Nutrition. The objective
of the Study was to determine if using Shakeology twice-daily can
improve weight loss and metabolic outcomes in healthy overweight
and obese adults. The benefits experienced by people in the study
align with many years of the results that Shakeology has delivered
to consumers. Accordingly, the people in the Shakeology group lost
more weight, saw decreases in cholesterol that were already in the
normal range and increases in the metabolic hormone adiponectin
than in the placebo group.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220322005713/en/
New clinical study provides further
evidence that The Beachbody Company’s Shakeology delivers weight
loss benefits to users. (Photo: Business Wire)
The Study was conducted by KGK Science Inc., an independent
contract research organization and wholly owned subsidiary of
Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA:
MY0). It was a 12-week, randomized, double-blinded and
placebo-controlled clinical trial that included a sample of 206
overweight and obese adults from 4 different locations in the US
and Canada. Participants in the Study were randomized to consume
Shakeology or a calorie-matched placebo 30 minutes before breakfast
and lunch, while following a calorie restricted diet for 12 weeks.
The primary outcome of the Study was weight loss that was
significantly greater in the Shakeology group than in the placebo
group.
The strengths of the Study included a large sample size and the
increased weight loss experienced by subjects over and above the
calorie-matched placebo. Greater weight loss indicated that the
benefits of Shakeology do not just stem from its calories, but also
from its additional ingredients including the protein, fiber,
superfood and phytonutrient blends that may contribute to the
benefits that people experience with the product. The most novel
finding from the Study was the increase in the metabolic hormone,
adiponectin, which is produced by adipose tissue in the body and
influences how a person’s body makes, uses and stores energy.
Dr. Heather Leidy, a member of The Beachbody Company Scientific
Advisory Board and an Associate Professor in the Department of
Nutrition at the University of Texas at Austin who collaborated on
the study said, “This study illustrated that the consumption of
nutrient-rich protein and fiber shakes, like Shakeology, can lead
to significant weight loss and uniquely increase the secretion of
adiponectin – which is a hormone that, in essence, supports normal
blood sugar levels and cardiovascular health. Thus, these findings
support the inclusion of nutritious shakes, containing protein and
fiber, to promote weight management and metabolic health.”
The Study is the second peer-reviewed, published study of
Shakeology sponsored by The Beachbody Company. Dr. Emily Fritz,
Beachbody’s Executive Director of Scientific Affairs, while talking
about the importance of conducting research on products noted, “We
develop products that are based on science, but we take it further
by continuing to conduct research that increases confidence in the
quality and efficacy of what we offer. We have thousands of success
stories about Shakeology and this new science helps provide further
evidence of the benefits people can experience with the
product.”
ABOUT KGK SCIENCE
Founded in 1997, KGK is a leading North American contract
research organization based in London, Ontario that primarily
provides high-quality clinical research trials with a focus on the
nutraceutical and emerging health care products. The business has
successfully helped hundreds of companies with custom designed
clinical trials and claim substantiation strategies to move
products into global markets. KGK’s other existing service lines
include expert regulatory support and compliance solutions,
participant recruitment, research support services and consulting
services. On an approximate basis, the business to date has
produced 150 publications, executed over 400 clinical trials across
more than 40 indications, amassed 25,000 participants in its
database and collected 10 million data points.
ABOUT WELLBEING DIGITAL SCIENCES
Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA:
MY0), is an evidence-based healthcare company focused on innovative
clinical solutions, artificial intelligence-powered digital
therapeutics and contract research. Its mission is supported by a
network of North American clinics that provide ketamine-assisted
therapies and other types of treatment to patients as well as
through a contract research organization that offers clinical
trials services to clients pursuing drug development. In essence,
the company exists to make breakthrough treatments more accessible
and to offer patients transformational experiences.
ABOUT THE BEACHBODY COMPANY, INC.
Headquartered in Southern California, The Beachbody Company is a
worldwide leading digital fitness and nutrition subscription
company, with over two decades of creating innovative content and
powerful brands. The Beachbody Company is the parent company to the
Beachbody On Demand streaming platform (BOD) with over 100 complete
fitness programs, 4,500 individual workouts, multiple nutrition
programs, and the connected Beachbody Bike by MYXfitness. For more
information, please visit TheBeachbodyCompany.com.
Forward Looking Statements: This
press release contains "forward-looking" statements pursuant to the
safe harbor provisions of the Securities Litigation Reform Act of
1995, which are statements other than historical fact or in the
future tense. These statements include but are not limited to,
statements regarding our future performance and our market
opportunity, including results of our products and related studies,
our business strategy, our plans, and our objectives and future
operations.
Forward-looking statements are based upon various estimates and
assumptions, as well as information known to us as of the date
hereof, and are subject to risks and uncertainties. Accordingly,
actual results could differ materially due to a variety of factors,
including: our ability to effectively compete in the fitness and
nutrition industries; our ability to successfully acquire and
integrate new operations; our reliance on a few key products;
market conditions and global and economic factors beyond our
control; intense competition and competitive pressures from other
companies worldwide in the industries in which we operate; and
litigation and the ability to adequately protect our intellectual
property rights. You can identify these statements by the use of
terminology such as "believe", “plans”, "expect", "will", "should,"
"could", "estimate", "anticipate" or similar forward-looking terms.
You should not rely on these forward-looking statements as they
involve risks and uncertainties that may cause actual results to
vary materially from the forward-looking statements. For more
information regarding the risks and uncertainties that could cause
actual results to differ materially from those expressed or implied
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to the "Risk Factors" section
of our Securities and Exchange Commission (SEC) filings, including
those risks and uncertainties included in the Form 10-K filed with
the SEC on March 1, 2022 and quarterly reports on Form 10-Q, which
are available on the Investor Relations page of the Beachbody
website at https://investors.thebeachbodycompany.com and on the SEC
website at www.sec.gov.
All forward-looking statements contained herein are based on
information available to us as of the date hereof and you should
not rely upon forward-looking statements as predictions of future
events. The events and circumstances reflected in the
forward-looking statements may not be achieved or occur. Although
we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
performance, or achievements. We undertake no obligation to update
any of these forward-looking statements for any reason after the
date of this press release or to conform these statements to actual
results or revised expectations, except as required by law. Undue
reliance should not be placed on forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220322005713/en/
ICR BeachbodyPR@icrinc.com
Beachbody (NYSE:BODY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Beachbody (NYSE:BODY)
Historical Stock Chart
From Apr 2023 to Apr 2024